Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to 0.96.

  • Viking Therapeutics' Equity Ratio fell 77.1% to 0.96 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.96, marking a year-over-year decrease of 77.1%. This contributed to the annual value of 0.97 for FY2024, which is 249.54% up from last year.
  • As of Q3 2025, Viking Therapeutics' Equity Ratio stood at 0.96, which was down 77.1% from 0.96 recorded in Q2 2025.
  • Over the past 5 years, Viking Therapeutics' Equity Ratio peaked at 0.98 during Q1 2025, and registered a low of 0.86 during Q4 2022.
  • Over the past 5 years, Viking Therapeutics' median Equity Ratio value was 0.96 (recorded in 2021), while the average stood at 0.95.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 1002.1% in 2022, then surged by 965.27% in 2023.
  • Viking Therapeutics' Equity Ratio (Quarter) stood at 0.96 in 2021, then decreased by 10.02% to 0.86 in 2022, then grew by 9.65% to 0.95 in 2023, then increased by 2.5% to 0.97 in 2024, then fell by 0.5% to 0.96 in 2025.
  • Its last three reported values are 0.96 in Q3 2025, 0.96 for Q2 2025, and 0.98 during Q1 2025.